I can start with that, and others may want to comment as well.
The joint oncology drug review process was initiated with many of the same principles as the common drug review. In fact, as that process moves along, the intention is for it to become part of the common drug review process.
It started with the western provinces identifying a need for some collaboration in the area of oncology. Saskatchewan and Manitoba both felt they had a need to advance in this area and were willing to spearhead the expansion. The common drug review had never included cancer drugs as part of its mandate because it was not within the mandate of the program.